ID

29196

Descripción

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01012037

Link

https://clinicaltrials.gov/show/NCT01012037

Palabras clave

Versiones (1)
  1. 6/3/18 6/3/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

6 de marzo de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes Mellitus, Type 2 NCT01012037

Inglés

Eligibility Diabetes Mellitus, Type 2 NCT01012037

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. diagnosis of type 2 diabetes mellitus.
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
2. current treatment with metformin alone (>/= 1500 mg or maximally tolerated dose) or metformin plus 1 other antidiabetic drug. metformin must be administered in twice daily dosing regimen. patients taking metformin three times daily can be included if posology is switched to twice daily and total daily dose is maintained.
Descripción

Metformin Dose Frequency | Antidiabetics Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0439603
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1265611
3. glycosylated haemoglobin (hba1c) is between 7.0% - 10.0%.
Descripción

Glucohemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0202054
4. body mass index (bmi) </=45 kg/m2.
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. treatment with extended release metformin.
Descripción

Metformin Extended Release

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C1707968
2. uncontrolled hyperglycaemia (fasting plasma glucose > 240 mg/dl or 13.3 mmol/l).
Descripción

Hyperglycemia Uncontrolled | Plasma fasting glucose measurement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020456
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0583513
3. myocardial infarction (mi), stroke or transient ischaemic attack (tia) within 6 months prior to informed consent.
Descripción

Myocardial Infarction | Cerebrovascular accident | Transient Ischemic Attack

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0007787
4. impaired hepatic or renal function, or gastric bypass surgery.
Descripción

Liver Dysfunction | Renal Insufficiency | Gastric Bypass

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C1565489
UMLS CUI [3]
C0017125
5. treatment with glitazones, glucagon like peptide-1 (glp-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent.
Descripción

Thiazolidinediones | GLP-1 Mimetics | Anti-Obesity Agents | Insulin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C3273809
UMLS CUI [3]
C0376607
UMLS CUI [4]
C0021641
6. current treatment with systemic steroids or change in dosage of thyroid hormones.
Descripción

Systemic steroids | Thyroid Hormones Dosage Change

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2825233
UMLS CUI [2,1]
C0040135
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0392747
7. alcohol or drug abuse within 3 months of informed consent.
Descripción

Substance Use Disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0038586
8. participation in another trial with investigational drug within 2 months prior to informed consent.
Descripción

Study Subject Participation Status | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
9. pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control.
Descripción

Premenopausal state | Breast Feeding | Pregnancy | Contraceptive methods Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232969
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032961
UMLS CUI [4,1]
C0700589
UMLS CUI [4,2]
C0332197
Volver a la parte superior de la página

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01012037

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
1. diagnosis of type 2 diabetes mellitus.
boolean
C0011860 (UMLS CUI [1])
Metformin Dose Frequency | Antidiabetics Quantity
Item
2. current treatment with metformin alone (>/= 1500 mg or maximally tolerated dose) or metformin plus 1 other antidiabetic drug. metformin must be administered in twice daily dosing regimen. patients taking metformin three times daily can be included if posology is switched to twice daily and total daily dose is maintained.
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,3])
C0935929 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Glucohemoglobin measurement
Item
3. glycosylated haemoglobin (hba1c) is between 7.0% - 10.0%.
boolean
C0202054 (UMLS CUI [1])
Body mass index
Item
4. body mass index (bmi) </=45 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metformin Extended Release
Item
1. treatment with extended release metformin.
boolean
C0025598 (UMLS CUI [1,1])
C1707968 (UMLS CUI [1,2])
Hyperglycemia Uncontrolled | Plasma fasting glucose measurement
Item
2. uncontrolled hyperglycaemia (fasting plasma glucose > 240 mg/dl or 13.3 mmol/l).
boolean
C0020456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0583513 (UMLS CUI [2])
Myocardial Infarction | Cerebrovascular accident | Transient Ischemic Attack
Item
3. myocardial infarction (mi), stroke or transient ischaemic attack (tia) within 6 months prior to informed consent.
boolean
C0027051 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0007787 (UMLS CUI [3])
Liver Dysfunction | Renal Insufficiency | Gastric Bypass
Item
4. impaired hepatic or renal function, or gastric bypass surgery.
boolean
C0086565 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
C0017125 (UMLS CUI [3])
Thiazolidinediones | GLP-1 Mimetics | Anti-Obesity Agents | Insulin
Item
5. treatment with glitazones, glucagon like peptide-1 (glp-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent.
boolean
C1257987 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
C0376607 (UMLS CUI [3])
C0021641 (UMLS CUI [4])
Systemic steroids | Thyroid Hormones Dosage Change
Item
6. current treatment with systemic steroids or change in dosage of thyroid hormones.
boolean
C2825233 (UMLS CUI [1])
C0040135 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0392747 (UMLS CUI [2,3])
Substance Use Disorders
Item
7. alcohol or drug abuse within 3 months of informed consent.
boolean
C0038586 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
8. participation in another trial with investigational drug within 2 months prior to informed consent.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Premenopausal state | Breast Feeding | Pregnancy | Contraceptive methods Absent
Item
9. pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control.
boolean
C0232969 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3])
C0700589 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial